Your best source on science and technology news from Turkmenistan
Provided by AGP
Indivior to Participate in Upcoming Investor Conferences
RICHMOND, Va., May 14, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced that it will participate in the following upcoming investor conferences:
-
2026 Jefferies Global Healthcare Conference – New York, NY – June 3rd
Joe Ciaffoni, Chief Executive Officer, and Ryan Preblick, Chief Financial Officer, will host 1x1 / group meetings on Wednesday, June 3rd and will also participate in a fireside chat on Wednesday, June 3rd at 11:05 a.m. U.S. EDT. Interested investors should contact their Jefferies representative to schedule a meeting. The fireside chat will be publicly available and can be accessed using the following weblink: Jefferies Webcast Link.
-
Goldman Sachs 47th Annual Global Healthcare Conference 2026 – Miami, FL – June 8th
Joe Ciaffoni, Chief Executive Officer, and Ryan Preblick, Chief Financial Officer, will host 1x1 / group meetings on Monday, June 8th. Interested investors should contact their Goldman Sachs representative to schedule a meeting.
About Indivior
As the leader in long-acting injectable treatments for opioid use disorder (OUD), Indivior is singularly focused on delivering evidence-based treatment and advancing understanding of OUD as a chronic but treatable brain disease. For more than 25 years, we have revolutionized the science of addiction medicine — developing treatments that help people move toward long-term recovery with independence and dignity. Building on this heritage, we are ushering in a new era, renewing our commitment to individuals living with OUD and carrying forward what matters most: compassion, integrity, and science. Together – with science, people living with OUD, public health champions, and communities, we are powering recovery and renewing hope. Visit https://www.indivior.com/ to learn more. Connect with Indivior on LinkedIn by visiting https://www.linkedin.com/company/indivior.
For Further Information
Investors:
Jason Thompson
Indivior Pharmaceuticals, Inc.
Tel: 804-402-7123
E-mail: jason.thompson@indivior.com
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
